Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyDisease description

Clinical presentation - signs and symptoms

10 evidence topics · 9 sources

Physician-reported signs and symptoms survey: US adults with MASH, 2019 and 2022

“We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fourteen prespecified individual physician-reported features of MASH were evaluated by the survey: fatigue, sleep disturbance, insomnia, general weakness, unexplained weight loss, hair loss, changes to personality, memory loss, jaundice, aching/discomfort in upper right abdomen, itchy skin, swelling in the legs/ankles/feet, tendency to bleed and bruise more easily, and swelling of the abdomen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 14 reported signs and symptoms, 11 were significantly associated with both physician-stated fibrosis stage and/or AASLD-derived risk category.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Physician-reported sign or symptom, n (%)Overall (n = 424)AASLD-derived low risk (n = 141)AASLD-derived indeterminate risk (n = 30)AASLD-derived high risk (n = 82)
None“167 (39.4)”View highlighted excerpt for this quote“58 (41.1)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“9 (11.0)”View highlighted excerpt for this quote
Constitutional symptoms: fatigue, sleep disturbance, and general weakness
Cognitive symptoms: memory loss and changes to personality
Signs of fluid retention, bleeding, and hepatic decompensation